Last reviewed · How we verify
NCT02848612: ANTICONEURORAD
Evaluation of the Amiens University Hospital Neuroradiology Anticoagulation Protocol
trial testing anticoagulation by unfractionated heparin in Aneurysm in 459 participants. Completed in 15 July 2016.
15 July 2016
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire, Amiens |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 459 |
| Start date | 20 November 2015 |
| Primary completion | 15 July 2016 |
| Estimated completion | 15 July 2016 |
| Sites | 1 location across France |
Drugs / interventions tested
- anticoagulation by unfractionated heparin — full drug profile →
Conditions studied
- Aneurysm — all drugs for Aneurysm →
Sponsor
Centre Hospitalier Universitaire, Amiens
Who can join
18 and older, any sex, with Aneurysm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To prevent thromboembolic complications, the embolization procedure is performed under prophylactic unfractionated heparin, the efficacy of which is monitored by point-of- care testing according to international guidelines. However, these guidelines are based on limited scientific evidence and the ideal level of anticoagulation required has not been precisely defined. Furthermore, the correlation between the point-of- care tests used at Amiens University Hospital and the reference methods used in the laboratory varies considerably according to the available literature.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02848612
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aneurysm
Currently open trials in the same condition.
- NCT06872684 — Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter ( · NA · recruiting
- NCT06689410 — Multimodal Biocollection Linked to the French Register of Intracranial Aneurysms · NA · recruiting
- NCT06793059 — Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD) · NA · recruiting
- NCT06235619 — Arch Size Study for Anatomical Variations · recruiting
- NCT06189950 — Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms:REBRIDGE · NA · recruiting
Other Centre Hospitalier Universitaire, Amiens trials
Trials by the same sponsor.
- NCT07354568 — Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock · recruiting
- NCT07071662 — Induction of Labor in Breech Presentation · completed
- NCT06909487 — Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respec · completed
- NCT07037719 — Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE) · recruiting
- NCT06996145 — Study of the Isometry of the Anterior Cruciate Ligament From the Center of the Native MRI Insertion Reported on Dynamic · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02848612 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire, Amiens
- Last refreshed: 12 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02848612.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing